Selected article for: "available evidence and respiratory disease"
Author: Carfora, Vincenzo; Spiniello, Giorgio; Ricciolino, Riccardo; Di Mauro, Marco; Migliaccio, Marco Giuseppe; Mottola, Filiberto Fausto; Verde, Nicoletta; Coppola, Nicola
Title: Anticoagulant treatment in COVID-19: a narrative review
  • Cord-id: wv4qu9xm
  • Document date: 2020_8_18
    • ID: wv4qu9xm
    Snippet: The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels. Thrombotic risk seems to be dir
    Document: The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels. Thrombotic risk seems to be directly related to disease severity and worsens patients’ prognosis. Therefore, the correct understanding of the mechanisms underlying COVID-19 induced prothrombotic state can lead to a thorough assessment of the possible management strategies. Hence, we review the pathogenesis and therapy of COVID 19-related thrombosis disease, focusing on the available evidence on the possible treatment strategies and proposing an algorithm for the anticoagulation strategy based on disease severity.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and lmwh molecular weight heparin: 1
    • ace inhibitor and lmwh therapy: 1
    • ace inhibitor and lmwh treatment: 1
    • ace inhibitor and low density: 1, 2
    • ace inhibitor and low density lipoprotein: 1, 2
    • ace inhibitor and low lmwh molecular weight heparin: 1
    • ace inhibitor and lung tissue: 1, 2, 3, 4
    • ace statins and acute renal failure: 1
    • acid derivative and active role: 1
    • acid derivative and activity inhibit: 1
    • acid derivative and adhesion molecule: 1
    • acid derivative and low density: 1
    • acid derivative and low density lipoprotein: 1
    • acid derivative and low mortality: 1